Latest New Zealand News

Commonwealth Bank of Australia reported a 5% increase in statutory net profit after tax to $5.367 billion for the half year ended December 2025, supported by lending growth and improved credit quality despite margin pressures and higher expenses. The bank declared a fully franked interim dividend of $2.35 per share.

Brightstar Resources has launched a $5 million Share Purchase Plan offering eligible shareholders discounted shares to fund key mining projects. The offer opens on 10 February and closes on 27 February 2026.

Regal Partners Global Investments Limited has updated its Dividend Reinvestment Plan to reflect its recent rebranding and remove participation barriers, effective immediately for the 1H26 interim dividend.

Revolution Private Credit Income Trust has launched a A$60 million institutional placement at A$2.00 per unit, aiming to bolster its investment in senior secured loans across Australia and New Zealand. The trust targets a net yield to maturity of 7.83%, emphasizing disciplined risk management and transparency.

Revolution Private Credit Income Trust (REV) has announced a $60 million wholesale placement at $2.00 per unit, aiming to broaden its exposure to Australian and New Zealand private debt markets. The move is expected to enhance portfolio diversification and liquidity for unitholders.

Amotiv Limited posted a resilient half-year result for December 2025, balancing modest revenue growth and margin pressures with strong cash flow and shareholder returns.

Foresta Group Holdings has formalised a 30-year lease for its Kawerau site in New Zealand, marking a pivotal step in advancing its integrated biomass manufacturing ambitions.

Australian Foundation Investment Company Limited has updated its interim and special dividend details, including foreign currency exchange rates and pricing for its Dividend Reinvestment and Substitution Share Plans.

PYC Therapeutics has initiated a substantial capital raising effort, aiming to secure up to A$653 million to propel its four RNA therapeutic candidates through critical clinical milestones. The retail entitlement offer opens today, following a successful institutional placement.

Scentre Group has announced an ordinary dividend of AUD 0.08905 per security for the six months ending December 2025, with a Dividend Reinvestment Plan option available. The full year results will be released on 24 February 2026.

Paradigm Biopharmaceuticals has entered a binding agreement with AVet Health to co-develop and license a novel oral therapy for veterinary osteoarthritis in Australia and New Zealand, unlocking new market potential while advancing its human clinical trials.

Algorae Pharmaceuticals has secured a key Licence & Supply Agreement with Cadila Pharmaceuticals to commercialise two generic cardiovascular and metabolic medicines in Australia and New Zealand, broadening its therapeutic reach beyond oncology.